Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SELA-070
- Development stage
- Phase 1
- Lead developer
- Cartesian Therapeutics
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
SELA-070 is a second-generation therapeutic vaccine developed as an immunostimulant for the treatment of tobacco use disorder and smoking cessation. It utilizes Selecta Biosciences' Synthetic Vaccine Particles (SVP) technology to deliver nicotine conjugated to nanoparticles that encapsulate immune-stimulating agents. The goal is to induce a strong and durable immune response by generating high levels of anti-nicotine antibodies, which bind inhaled nicotine and prevent it from crossing the blood-brain barrier, thereby reducing its addictive effects. The drug has reached Phase 1 clinical trials with support from the National Institutes of Health[1][2][5].
Beyond the preview
Go deeper on SELA-070.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SELA-070.